“We are also adjusting our bridging program to further ensure that it's utilized for people with type 2 diabetes, which will impact new start volume but should impact net revenue.”

In context

“the short term. If you're too short term-focused, then you're going to be driven to gain access quickly and not make the right pricing decisions. So we thought the bridging program tied with the disciplined negotiation approach was the best approach. And that's the one we've taken and that's the 1 we've held true to during our launch. So what we'll see is net price will increase as we gain payer access. In the third quarter, we had 22% of people with commercial and Part D insurance had formerly access Mounjaro. As of October 1, that jumped to 45%. And what we anticipate is we'll still take a disciplined moderated approach to make sure we get the best access for the right price point. And we're still very confident that we will grow and we'll achieve broad access in the upcoming future. We are also adjusting our bridging program to further ensure that it's utilized for people with type 2 diabetes, which will impact new start volume but should impact net revenue. So we expect over the upcoming quarters that net price will grow for Mounjaro. As it comes to supply, our supply chain has performed exceptionally well since launch. We're taking actions to maximize production supply for our current facilities while we ramp up our new manufacturing facilities that you referenced. The U.S. Mounjaro launch is really unprecedented with a viral nature given just tremendous patient satisfaction and the visible results that people experience that really spark many conversations with them, the type 2 diabetes community, which then brings greater interest in the type 2 diabetes committee, our community for Mounjaro. But it is a dynamic situation, given the uncertainty of competitor GLP supply and that Mounjaro patient prescription abandonment long-term adherence”